托珠单抗单药治疗对类风湿关节炎患者报告结局的影响:两项随机对照试验分析
基于AMBITION和ADACTA两项随机对照试验,比较托珠单抗单药与甲氨蝶呤或阿达木单药治疗类风湿关节炎患者报告结局的改善。结果显示,托珠单抗组在HAQ、疲劳、SF-36等多个维度改善更显著,更多患者达到临床意义改善和年龄性别匹配常模值。
要点
- 托珠单抗单药较甲氨蝶呤显著改善HAQ、疲劳及SF-36多个维度。
- 托珠单抗单药较阿达木单药显著改善患者总体评估、疼痛及SF-36精神维度。
- 托珠单抗组更多患者达到临床意义改善和常模值。
核心结论
- 托珠单抗单药治疗使更多类风湿关节炎患者报告临床意义的患者报告结局改善及达到常模值。
研究设计与样本
- 基于AMBITION(NCT00109408)和ADACTA(NCT01119859)两项随机对照试验,比较托珠单抗单药与甲氨蝶呤或阿达木单药治疗类风湿关节炎患者报告结局。
主要发现
- AMBITION中,托珠单抗组第24周HAQ平均改善-0.7 vs 甲氨蝶呤组-0.5,FACIT-疲劳8.7 vs 5.7,SF-36 PCS 9.8 vs 7.8。
- ADACTA中,托珠单抗组患者总体评估平均改善-42.3 vs 阿达木组-31.8,疼痛-40.1 vs -28.7,SF-36 MCS 7.9 vs 5.0。
- AMBITION中,托珠单抗组45.0%-84.0%患者达到≥MCID改善,24.3%-52.1%达到≥常模值;甲氨蝶呤组分别为39.4%-81.8%和14.5%-45.0%。
- ADACTA中,托珠单抗组57.7%-83.3%患者达到≥MCID改善,22.1%-49.3%达到≥常模值;阿达木组分别为13.6%-37.8%。
临床怎么用
- 对于类风湿关节炎患者,托珠单抗单药治疗可考虑用于改善患者报告结局如功能、疲劳和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA. METHODS: PROs included patient global assessment (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and Short Form-36 (SF-36) physical component summary (PCS) and mental component summary (MCS) and eight domain scores. Outcomes included proportions of patients reporting changes from baseline in PRO scores ≥minimum clinically important differences (MCID) and ≥age-matched and gender-matched normative values at 24 weeks. RESULTS: In AMBITION, TCZ-treated patients reported significantly greater mean improvements in HAQ (-0.7 vs -0.5), FACIT-Fatigue (8.7 vs 5.7), SF-36 PCS (9.8 vs 7.8) and five SF-36 domains at week 24 than with MTX; 45.0%-84.0% of TCZ-treated patients reported improvements ≥MCID, and 24.3%-52.1% reported scores ≥normative values across all PROs versus 39.4%-81.8% and 14.5%-45.0%, respectively, with MTX. In ADACTA, TCZ-treated patients reported significantly greater improvements in PtGA (-42.3 vs -31.8), pain (-40.1 vs -28.7), SF-36 MCS (7.9 vs 5.0) and three SF-36 domains than with ADA; 57.7%-83.3% of TCZ-treated patients reported improvements ≥MCID, and 22.1%-49.3% reported scores ≥normative values across all PROs versus 13.6%-37.8%, respectively, with ADA. CONCLUSIONS: TCZ monotherapy resulted in more patients reporting clinically meaningful PRO improvements and PRO scores ≥normative values compared with MTX or ADA monotherapy. TRIAL REGISTRATION NUMBERS: NCT00109408 and NCT01119859; Post-results.
引用
- Strand V, Michalska M, Birchwood C, et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open. 2017. PMID: 28955499. doi:10.1136/rmdopen-2017-000496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。